Phase I Data on Rexahn's Supinoxin - Analyst Blog

By
A A A

Rexahn Pharmaceuticals, Inc. ( RNN ) announced initial data from its ongoing phase I dose-escalation study on Supinoxin (RX-5902). The drug was well tolerated in cancer patients with solid tumors.

The study is evaluating the safety, tolerability and dose limiting toxicities of Supinoxin as well as maximal tolerated dose (MTD) in patients suffering from solid cancer tumors who have failed prior treatment with other approved therapies and whose disease has progressed.

Rexahn has completed three dosing cycles (25mg, 50mg and 100 mg) in the ongoing study. So far, no adverse incidents related to the dosing of Supinoxin have occurred and the fourth dosing cycle with 150 mg of Supinoxin has been initiated. The MTD is yet to be achieved. Initial data from the study showed that the pharmacokinetic profile and oral bioavailability of Supinoxin was similar to that observed in preclinical studies.

Meanwhile, Rexahn is advancing with its other oncology candidates, Archexin and RX-3117. Archexin is in a phase IIa proof-of-concept study in patients suffering from metastatic renal cell carcinoma (RCC). Additionally, RX-3117 is in a phase Ib study in patients with solid tumors. The company expects to complete enrolling patients for this study by the end of 2014. Data readout is expected in the first half of 2015.

We expect investor focus to remain on pipeline updates from the company.

Rexahn carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Alexion Pharmaceuticals, Inc. ( ALXN ), Amgen Inc. ( AMGN ) and Gilead Sciences Inc. ( GILD ). All these stocks carry a Zacks Rank #1 (Strong Buy). 



ALEXION PHARMA (ALXN): Free Stock Analysis Report

AMGEN INC (AMGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

REXAHN PHARMACT (RNN): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: MTD , ALXN , AMGN , GILD , RNN

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Russell’s One Good Reason
Russell’s One Good Reason           
Tammy’s One Good Reason
Tammy’s One Good Reason             
Lisa’s One Good Reason
Lisa’s One Good Reason              
Tammy’s #OneGoodReason
Tammy’s #OneGoodReason              

Stocks

Referenced

Most Active by Volume

69,664,063
  • $7.43 ▲ 24.04%
55,112,364
  • $8.93 ▼ 5.20%
51,324,828
  • $17.14 ▲ 0.65%
32,859,233
  • $75.18 ▲ 1.44%
32,551,476
  • $33.8001 ▲ 3.74%
29,290,663
  • $101.22 ▲ 1.20%
26,432,382
  • $107.63 ▲ 0.61%
26,397,662
  • $11.77 ▲ 3.98%
As of 10/31/2014, 02:30 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com